ECSP22080683A - 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52 - Google Patents

3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52

Info

Publication number
ECSP22080683A
ECSP22080683A ECSENADI202280683A ECDI202280683A ECSP22080683A EC SP22080683 A ECSP22080683 A EC SP22080683A EC SENADI202280683 A ECSENADI202280683 A EC SENADI202280683A EC DI202280683 A ECDI202280683 A EC DI202280683A EC SP22080683 A ECSP22080683 A EC SP22080683A
Authority
EC
Ecuador
Prior art keywords
pyrazines
substituted
phenoxyazetidine
agonist activity
phenoxyazetidin
Prior art date
Application number
ECSENADI202280683A
Other languages
English (en)
Inventor
Marco Ferrara
Graeme Semple
Giacomo Fossati
Ursula Mueller-Vieira
Kai Gerlach
Scott Hobson
Julian Wippich
Yifeng Xiong
Uta Friederike Lessel
Frank Runge
Barbara Bertani
Original Assignee
Boehringer Ingelheim Int
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Arena Pharm Inc filed Critical Boehringer Ingelheim Int
Publication of ECSP22080683A publication Critical patent/ECSP22080683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a 3-fenoxiazetidin-1-il-pirazinas sustituidas de la fórmula general (I) que son agonistas de GPR52, útiles en el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. Además, la invención se refiere a 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) para su uso como medicamento, composiciones farmacéuticas que comprenden 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) y procesos para preparar composiciones farmacéuticas, así como procesos para fabricar los compuestos según la invención.
ECSENADI202280683A 2020-03-30 2022-10-18 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52 ECSP22080683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
ECSP22080683A true ECSP22080683A (es) 2022-11-30

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202280683A ECSP22080683A (es) 2020-03-30 2022-10-18 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52

Country Status (18)

Country Link
US (1) US11780827B2 (es)
EP (1) EP4126850B1 (es)
JP (1) JP2023522307A (es)
KR (1) KR20220161454A (es)
CN (1) CN115697997A (es)
AR (1) AR121675A1 (es)
AU (1) AU2021250303A1 (es)
BR (1) BR112022018996A2 (es)
CA (1) CA3176265A1 (es)
CO (1) CO2022014886A2 (es)
CR (1) CR20220554A (es)
DO (1) DOP2022000203A (es)
EC (1) ECSP22080683A (es)
IL (1) IL296823A (es)
MX (1) MX2022012067A (es)
PE (1) PE20221918A1 (es)
TW (1) TW202204343A (es)
WO (1) WO2021198149A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230131465A1 (en) 2021-09-14 2023-04-27 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
JPWO2011093352A1 (ja) 2010-01-27 2013-06-06 武田薬品工業株式会社 チアゾール誘導体
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
ES2784316T3 (es) * 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
CA2998491A1 (en) * 2015-09-17 2017-03-23 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
CN115697997A (zh) 2023-02-03
US20220356172A1 (en) 2022-11-10
BR112022018996A2 (pt) 2022-11-01
KR20220161454A (ko) 2022-12-06
US11780827B2 (en) 2023-10-10
DOP2022000203A (es) 2022-11-30
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
MX2022012067A (es) 2022-10-13
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
IL296823A (en) 2022-11-01
CA3176265A1 (en) 2021-10-07
WO2021198149A1 (en) 2021-10-07
CR20220554A (es) 2023-01-09
JP2023522307A (ja) 2023-05-30
PE20221918A1 (es) 2022-12-29
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29

Similar Documents

Publication Publication Date Title
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2017002650A1 (es) Compuestos novedosos
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CU20130033A7 (es) Imidazopiridazinas sustituidas
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CO2022008313A2 (es) Compuestos químicos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2022018636A2 (es) Moduladores de il-17a
CO2022016899A2 (es) Moduladores de il-17a
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
UY31812A (es) Derivados de cinolina como inhibidores de csf-1
UY30699A1 (es) Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
AR123685A1 (es) Antagonistas del mrgx2